Linagliptin ( trade names Tradjenta and Trajenta,cas 668270-12-0) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.Linagliptin (cas 668270-12-0) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.
Viwit Pharmaceuticals Limited (Viwit), founded in 2006, is a fast-growing research-based pharmaceutical healthcare company dedicated to the development, manufacture and marketing of innovative products in the fields of Finished Dosage Formulations, Active Pharmaceutical Ingredients and Fine Chemicals. Viwit manufactures all the products based on company’s core technologies, and is dedicated to serve customers for their greater success and healthier living.
Viwit consists of six subsidiaries, in...
View more >>
Basic Information
Business Type: Manufacturer
Product/Service (We Buy): 101 - 500 People
Year Established: 2006
Number of Employees: 101 - 500 People
Trade & Market
Main Markets: North America,Mid East,Western Europe
China
